Analyst Ratings for Orthopedics CHILDREN last quarter range from bullish to bearish, as provided by 6 analysts.
The table below provides a snapshot of their recent ratings, showing how sentiments have evolved over the past 30 days and comparing them to previous months.
| Bullish | A little bullish | Indifferent | A little bearish | Bearish | |
|---|---|---|---|---|---|
| Total ratings | 3 | 1 | 2 | 0 | 0 |
| Last 30 days | 1 | 0 | 0 | 0 | 0 |
| 1 million ago | 0 | 0 | 0 | 0 | 0 |
| 2 million ago | 2 | 1 | 1 | 0 | 0 |
| 3 million ago | 0 | 0 | 1 | 0 | 0 |
Analysts have set 12-month price targets for OrthoPediatrics, revealing an average target of $36.83, a high estimate of $50.00 and a low estimate of $31.00. Looking at an increase of 8.32%, the current average has risen from the previous average price target of $34.00.
Breaking down analyst ratings: A detailed examination
By examining recent analyst actions, we gain insight into how financial experts perceive orthopedics. The following summary outlines key analysts, their recent ratings, and adjustments to ratings and price targets.
| Analyst | Analytics company | Action taken | Assessment | Current price target | Previous price target |
|---|---|---|---|---|---|
| Mike Matson | Needham | Maintains | Acquire | $37.00 | – |
| Samuel Brodovsky | Fiduciary Securities | Raise | Jack | $32.00 | $31.00 |
| Wise Rick | Stifel | Raise | Acquire | $34.00 | $32.00 |
| Mike Matson | Needham | Maintains | Acquire | $37.00 | – |
| David Turkaly | JMP Titles | Maintains | Market outperformance | $50.00 | – |
| Kaila Krum | Fiduciary Securities | Lower | Jack | $31.00 | $39.00 |
Key Insights:
- Action taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they “maintain,” “raise,” or “lower” their position, this indicates their reaction to recent developments related to orthopedics. This view provides a snapshot of analysts’ perspectives on the current state of the company.
- Assessment: Offering a comprehensive view, analysts rate stocks qualitatively, ranging from “Outperform” to “Underperform”. These ratings convey expectations for OrthoPediatrics’ relative performance compared to the broader market.
- Price targets: Analysts review price target adjustments, providing estimates for OrthoPediatrics’s future value. Comparing current and previous targets offers insight into analysts’ evolving expectations.
To get a panoramic view of OrthoPediatrics’s market performance, explore these analyst ratings along with essential financial indicators. Stay informed and make judicious decisions using our ratings table.
Stay updated on the ratings of OrthoPediatrics analysts.
If you’re interested in following the news and performance of small-cap stocks, you can start by tracking them here.
Information on orthopedics
OrthoPediatrics Corp is a medical device company. The company is engaged in supplying products to the pediatric orthopedic market. The company designs, develops and markets implants and instruments to meet the needs of surgeons and patients. Its products include PediLoc, PediPlates, cannulated screws, PediFlexTM nail, PediNailTM, PediLoc Tibia and ACL reconstruction system, among others.
Financial insights: orthopedics
Market capitalization analysis: Falling below industry benchmarks, the company’s market capitalization reflects a small size relative to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.
Positive revenue trend: Examining OrthoPediatrics’ financials over 3 months reveals a positive narrative. The company has achieved a noteworthy revenue growth rate 21.36% as of December 31, 2023, showing a substantial increase in top-line earnings. Compared to competitors, the company exceeded expectations with a growth rate above average for healthcare peers.
Net margin: OrthoPediatrics’ net margin is below industry standards, indicating difficulty achieving strong profitability. With a clear margin of -17.79%, the company may face difficulties in effectively controlling costs.
Return on equity (ROE): OrthoPediatrics’ ROE stands out, exceeding industry averages. With an impressive ROE of -1.78%the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): The company’s ROA is lower than industry benchmarks, signaling potential difficulties in using resources efficiently. With an ROA of -1.54%, the company may face challenges in generating satisfactory returns from its assets.
Debt Management: With a below-average debt-to-equity ratio of 0.03OrthoPediatrics adopts a prudent financial strategy, indicating a balanced approach to debt management.
Analyst Ratings: Simplified
Ratings come from analysts or banking and financial systems specialists who report for specific stocks or defined sectors (typically once a quarter for each stock). Analysts usually draw their information from company conference calls and meetings, financial statements, and conversations with key industry insiders to make their decisions.
Analysts can supplement their ratings with forecasts on metrics such as growth estimates, earnings and revenues, giving investors a more complete perspective. However, investors should keep in mind that analysts, like any human, can have subjective perspectives that influence their forecasts.
This article was generated by Benzinga’s automated content engine and reviewed by an editor.